Page last updated: 2024-08-24

fradafiban and Coronary Disease

fradafiban has been researched along with Coronary Disease in 2 studies

*Coronary Disease: An imbalance between myocardial functional requirements and the capacity of the CORONARY VESSELS to supply sufficient blood flow. It is a form of MYOCARDIAL ISCHEMIA (insufficient blood supply to the heart muscle) caused by a decreased capacity of the coronary vessels. [MeSH]

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (50.00)	18.2507
2000's	1 (50.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Byrne, A; Crean, P; Fitzgerald, DJ; Maher, M; Moran, N; Walsh, N	1
Akkerhuis, KM; Baardman, T; Deckers, JW; Hoffmann, J; Peels, HO; Simoons, ML; Stibbe, J; Suryapranata, H; van Den Brand, MJ; van Der Wieken, LR; van Der Zwaan, C	1

Trials

2 trial(s) available for fradafiban and Coronary Disease

Article	Year
Continued thromboxane A2 formation despite administration of a platelet glycoprotein IIb/IIIa antagonist in patients undergoing coronary angioplasty. Arteriosclerosis, thrombosis, and vascular biology, 1997, Volume: 17, Issue:11 Topics: Administration, Oral; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Biphenyl Compounds; Bleeding Time; Cell Division; Coronary Disease; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Fibrinogen; Heparin; Humans; Infusions, Intravenous; Male; Middle Aged; Muscle, Smooth, Vascular; P-Selectin; Pilot Projects; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Pyrrolidines; Thrombosis; Thromboxane A2; Thromboxane B2; Vasoconstriction	1997
Pharmacodynamics and safety of lefradafiban, an oral platelet glycoprotein IIb/IIIa receptor antagonist, in patients with stable coronary artery disease undergoing elective angioplasty. Heart (British Cardiac Society), 2001, Volume: 85, Issue:4 Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Area Under Curve; Biphenyl Compounds; Coronary Disease; Double-Blind Method; Female; Hemorrhage; Hemostasis; Humans; Logistic Models; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prodrugs; Pyrrolidines; Risk	2001

Article

Year

Continued thromboxane A2 formation despite administration of a platelet glycoprotein IIb/IIIa antagonist in patients undergoing coronary angioplasty.

Arteriosclerosis, thrombosis, and vascular biology, 1997, Volume: 17, Issue:11

Topics: Administration, Oral; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Biphenyl Compounds; Bleeding Time; Cell Division; Coronary Disease; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Fibrinogen; Heparin; Humans; Infusions, Intravenous; Male; Middle Aged; Muscle, Smooth, Vascular; P-Selectin; Pilot Projects; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Pyrrolidines; Thrombosis; Thromboxane A2; Thromboxane B2; Vasoconstriction

1997

Pharmacodynamics and safety of lefradafiban, an oral platelet glycoprotein IIb/IIIa receptor antagonist, in patients with stable coronary artery disease undergoing elective angioplasty.

Heart (British Cardiac Society), 2001, Volume: 85, Issue:4

Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Area Under Curve; Biphenyl Compounds; Coronary Disease; Double-Blind Method; Female; Hemorrhage; Hemostasis; Humans; Logistic Models; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prodrugs; Pyrrolidines; Risk

2001